Teva completes acquisition of Allergan generics arm
Teva Pharmaceutical completes $40 billion acquisition of the generics arm of rival Allergan.
Teva Pharmaceutical completes $40 billion acquisition of the generics arm of rival Allergan.
Israeli pharmaceutical company wins regulatory approval for acquisition of Allergan, conditional upon giving up some of its products.
$40.5 billion purchase solidifies Teva as world leader in generic drugs, after $40.1 billion bid for rival Mylan meets resistance.